Echo Therapeutics Hires Marketing Executive
Published on Wednesday, 30 May 2012 08:21 Written by TradersHuddle Staff
Company continues to move Symphony® tCGM System toward commercialization
PHILADELPHIA, May 30, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that David Walton, who has nearly two decades of strategic healthcare marketing experience, has joined Echo Therapeutics' management team at a critical stage in company growth. Mr. Walton will report to CEO Patrick Mooney, M.D.
David Walton joins as Vice President of Marketing and Commercial Development, leading global strategic marketing planning for Echo's Symphony tCGM System and other new products in the Company's growth strategy.
"We are extremely pleased to welcome David to Echo's management team. Dave brings an extensive track record of business strategy, healthcare marketing, and product development expertise to Echo," said Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics. "We look forward to benefiting from Dave's substantial knowledge to lead Symphony from product development to global commercialization."
Mr. Walton brings 17 years of healthcare marketing and strategic planning experience to Echo. He joins Echo from Johnson & Johnson's Diabetes Care Franchise, where he most recently served as Worldwide Director, Global Strategic Marketing for Insulin Delivery and Continuous Glucose Monitoring products at LifeScan. During his 11 years at J&J, he worked in a number of therapeutic areas, including Diabetes, ADHD, Parkinson's Disease and Oncology and has received several J&J Standards of Leadership Awards. Prior to J&J, Mr. Walton spent 6 years in healthcare consulting at Deloitte Consulting and Bogart Delafield Ferrier working on various strategy and marketing engagements for health plans, hospital systems and pharmaceutical, biotech and medical device clients. He earned his BA degree in Psychology from Princeton University and an MBA in Healthcare Management from the Wharton School at the University of Pennsylvania.
About Echo Therapeutics
Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.
For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
SOURCE Echo Therapeutics, Inc.
- Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter
- Echo Therapeutics Announces Pricing of Public Offering of Common Stock
- Echo Therapeutics Submits Pre-Submission Package to FDA for Symphony® CGM System
- Echo Therapeutics Announces Reverse Split of Common Stock
- Echo Therapeutics Initiates CE Mark Clinical Trial of its Symphony® CGM System
- Echo Therapeutics to Present at the Jefferies Global Healthcare Conference
- Notified Body Accepts Echo Therapeutics' Clinical Trial Plan for Symphony® CGM System
- Echo Therapeutics Announces Successful Unveiling of Symphony® CGM System
- Echo Therapeutics Announces Institutional Review Board (IRB) Approval for Its Clinical Trial of the Symphony® CGM System
- Echo Therapeutics to Unveil Symphony® CGM System in Webcast
Related Partner Headlines
- Echo Therapeutics Announces $20 Million Financing with Platinum-Montaur Life Sciences - Benzinga
- UPDATE: Ascendiant Capital Markets Initiates Buy, $2 PT on Echo Therapeutics - Benzinga
- UPDATE: Wunderlich Securities Initiates Coverage of Echo Therapeutics with Hold Rating, $1.75 PT - Benzinga
- Echo Therapeutics Presents Positive Clinical Trial Results of the Symphony tCGM System at the American Diabetes Association's 72nd Scientific Sessions - Benzinga
- UPDATE: Feltl and Company Downgrades Echo Therapeutics to Buy, Lowers PT - Benzinga
- Echo Therapeutics Announces Positive Clinical Trial Results of Symphony® tCGM System - Benzinga
Latest Partner Headlines
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com
Separating the Bargains From the Busts - TheStreet.com
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com
Gap Up and Sit - TheStreet.com
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com
Windows 8 PC Sales Disappointing: Report - TheStreet.com
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Dow JonesCompany ID [INDEXDJX:.DJI] Last trade:15,112.19 Trade time:4:52PM EDT Value change:▼206.04 (-1.35%)
S&P 500Company ID [INDEXSP:.INX] Last trade:1,628.93 Trade time:4:52PM EDT Value change:▼22.88 (-1.39%)
NASDAQCompany ID [INDEXNASDAQ:.IXIC] Last trade:3,443.20 Trade time:5:15PM EDT Value change:0.00 (0.00%)
In The Wires
PTC Therapeutics Prices Initial Public Offering
Amdocs Unveils Packaged Software and Hardware for Real-Time Charging, Deployable in Four Months*
Amdocs Showcases Full Range of Solutions and Services to Help Service Providers Unlock the Value of Big Data Analytics
XL Axiata Deploys Amdocs Mobile Payments for Direct Carrier Billing
Sirtex To Distribute Surefire Medical's Innovative Infusion System in Australia and Asia Pacific Markets
Northrop Grumman to Provide Fuel Quantity Indicator System for UK's Sentry E-3D AWACS Aircraft
Men's Wearhouse Declares Quarterly Cash Dividend
One-Third of Companies Have Missed Revenue Goals in the Last Year